Vanda Pharmaceuticals (VNDA) Long-Term Deferred Tax (2010 - 2025)

Vanda Pharmaceuticals (VNDA) has 9 years of Long-Term Deferred Tax data on file, last reported at $103.1 million in Q3 2025.

• For the quarter ending Q3 2025, Long-Term Deferred Tax rose 29.88% year-over-year to $103.1 million; the trailing twelve-month figure through Sep 2025 stood at $103.1 million (up 29.88% YoY), and the FY2024 full-year result was $81.4 million, up 8.59% from the prior year.
• Long-Term Deferred Tax improved to $103.1 million in Q3 2025, from $97.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $103.1 million in Q3 2025 to a low of $67.8 million in Q3 2023.
• A 5-year average of $78.4 million and a median of $75.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax retreated 11.89% in 2022 and grew 29.88% in 2025, its largest moves.
• Tracing VNDA's Long-Term Deferred Tax over 5 years: stood at $74.9 million in 2021, then retreated by 1.12% to $74.0 million in 2022, then gained by 1.3% to $75.0 million in 2023, then gained by 8.59% to $81.4 million in 2024, then rose by 26.56% to $103.1 million in 2025.
• Business Quant data shows VNDA's Long-Term Deferred Tax at $103.1 million in Q3 2025, $97.1 million in Q2 2025, and $89.1 million in Q1 2025.